financetom
META
financetom
/
Communication Services
/
META
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Meta Platforms, Inc.META
616.46USD
+3.69 (0.60%)
Jan 21, 2025, 4:00 PM - At close
621.55USD
+5.09 (0.83%)
Jan 21, 2025, 7:55 PM EST - Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
1.56T
Revenue (ttm)
156.23B
Net Income (ttm)
55.54B
Shares Out
2.52B
EPS (ttm)
21.18
PE Ratio
29.11
Forward PE
25.34
Dividend
$2.00 (0.32%)
Ex-Dividend Date
Dec 16, 2024
Volume
11,483,588
Open
617.83
Previous Close
612.77
Day's Range
609.01 - 621.50
52-Week Range
382.08 - 638.40
Beta
1.19
Analysts
Strong Buy
Price Target
649.82 (+5.41%)
Earnings Date
Jan 29, 2025
Description >

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide.

It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately.

The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere.

The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021.

Meta Platforms, Inc. was incorporated in 2004 and is headquartered in Menlo Park, California.

Latest News >
Concentrix Fiscal Q4 Non-GAAP EPS Falls, Revenue Rises; Guidance Set -- Shares Fall After Hours
Concentrix Fiscal Q4 Non-GAAP EPS Falls, Revenue Rises; Guidance Set -- Shares Fall After Hours
Jan 15, 2025
04:23 PM EST, 01/15/2025 (MT Newswires) -- Concentrix ( CNXC ) reported fiscal Q4 non-GAAP diluted earnings late Wednesday of $3.26 a share, down from $3.36 a year earlier. Four analysts surveyed by FactSet expected $3.02. Revenue in the quarter ended Nov. 30 was $2.45 billion, up from $2.23 billion a year earlier. Analysts surveyed by FactSet expected $2.44 billion....
H.B. Fuller Fiscal Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance
H.B. Fuller Fiscal Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance
Jan 15, 2025
04:22 PM EST, 01/15/2025 (MT Newswires) -- H.B. Fuller Company ( FUL ) late Wednesday reported fiscal Q4 adjusted diluted earnings of $0.92 per share, down from $1.32 a year earlier. Analysts polled by FactSet expected $1.00. Net revenue for the quarter ended Nov. 30 was $923.3 million, up from $902.9 million a year earlier. Analysts surveyed by FactSet expected...
Artis REIT Announces Quarterly Cash Distribution
Artis REIT Announces Quarterly Cash Distribution
Jan 15, 2025
04:23 PM EST, 01/15/2025 (MT Newswires) -- Artis Real Estate Investment Trust (AX-UN.TO) after close of trade Wednesday declared a quarterly cash distribution of $0.4370625 per Series I preferred unit of Artis for the quarter ending Jan. 31. The cash distributions will be made on Jan. 31, 2025, to Series I Unitholders of record on Jan. 31. There are an...
Eli Lilly Gets FDA Approval for Omvoh to Treat Crohn's Disease
Eli Lilly Gets FDA Approval for Omvoh to Treat Crohn's Disease
Jan 15, 2025
04:25 PM EST, 01/15/2025 (MT Newswires) -- Eli Lilly ( LLY ) said the US Food and Drug Administration granted expanded approval for Omvoh to treat adult patients with moderate to severe active Crohn's disease in adults. The approval is based on results from a phase 3 study that showed 53% of patients treated with Omvoh had clinical remission and...
Copyright 2023-2025 - www.financetom.com All Rights Reserved